Burzynski Research Institute Inc (BZYR)
Sector • Healthcare Industry • In Vitro & In Vivo Diagnostic Substances |
Industry • In Vitro & In Vivo Diagnostic Substances |
Sector • Healthcare |
News
Burzynski Research Institute Inc Faces Operating Shortfall, Raises Stockholder Concerns
The company declared operating shortfall in the second quarter of 2023
published operating deficit of $-0.231737 millions, in the March to May 31 2022
Among many companies, the disclosed also its fourth quarter of 2022 effort